Phibro Animal Health Corporation (FRA:PB8)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.04B +20.8% |
| Revenue (ttm) | 1.30B +26.0% |
| Net Income | 82.60M +199.6% |
| EPS | 2.02 +198.7% |
| Shares Out | n/a |
| PE Ratio | 12.63 |
| Forward PE | 9.03 |
| Dividend | 0.42 (1.64%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | n/a |
| Open | 24.20 |
| Previous Close | 25.40 |
| Day's Range | 24.20 - 24.20 |
| 52-Week Range | 20.40 - 50.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Phibro Animal Health
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional ... [Read more]
Financial Performance
In fiscal year 2025, Phibro Animal Health's revenue was $1.30 billion, an increase of 27.37% compared to the previous year's $1.02 billion. Earnings were $48.26 million, an increase of 1897.68%.
Financial numbers in USD Financial StatementsNews
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference. Executive Vice President, Corporate Strategy &...
Phibro Animal Health price target lowered to $44 from $62 at Citi
Citi lowered the firm’s price target on Phibro Animal Health (PAHC) to $44 from $62 and keeps a Neutral rating on the shares.
Phibro Animal Health Transcript: Bank of America Global Healthcare Conference 2026
Strong quarterly growth was driven by broad portfolio performance and recent acquisitions, with continued margin expansion expected. Regulatory changes in Brazil will create short-term headwinds, but operational experience and new sustainability initiatives, including a carbon-negative feed additive, position the business for long-term growth.
Phibro Animal Health price target lowered to $44 from $62 at Citi
In a sector note on U.S. HealthTech & Distribution, Citi lowered the firm’s price target on Phibro Animal Health (PAHC) to $44 from $62 and keeps a Neutral rating on…
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America Securities Health Care Conference. Executive Vice President, ...
Phibro Animal Health Earnings Call Transcript: Q3 2026
Q3 2026 saw 10% sales growth and 11% higher Adjusted EBITDA, led by Animal Health. FY2026 guidance was raised across all key metrics, with regulatory and geopolitical risks incorporated. New sustainability initiatives and a leadership transition were highlighted.
Phibro Animal Health Quarterly report: Q3 2026
Phibro Animal Health has published its Q3 2026 quarterly earnings report on May 7, 2026.
Phibro Animal Health Earnings release: Q3 2026
Phibro Animal Health released its Q3 2026 earnings on May 7, 2026, summarizing the period's financial results.
Phibro Animal Health Slides: Q3 2026
Phibro Animal Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on May 7, 2026.
Phibro Animal Health reports Q3 adjusted EPS 76c, consensus 71c
Reports Q3 revenue $383.5M, consensus $367.02M. “Phibro delivered a strong third quarter, with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million,” said Jack…
Phibro Animal Health raises FY26 EPS view to $2.98-$3.10 to $2.93-$3.10
Consensus $3.03. Raises FY26 revenue view to $1.46B-$1.5B from $1.45B-$1.5B, consensus $1.49B.
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2026, and its update...
Phibro Animal Health Corporation Declares Quarterly Dividend
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Cla...
Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the launch of its new Sustainable Solutions Platform (SSP), a companywide initiative designed to help an...
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 6, 2026, after the market closes. Phibro manag...
Phibro Animal Health discloses new framework on antimicrobials in Brazil
Phibro Animal Health (PAHC) “announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Brazil that have growth promotion indications. The Brazilian...
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Bra...
Phibro Animal Health initiated with a Neutral at Citi
Citi initiated coverage of Phibro Animal Health (PAHC) with a Neutral rating and $62 price target The firm launched the animal health and dental sectors with a “cautiously optimistic” view.
Phibro Animal Health Transcript: BofA Securities Animal Health Summit
Strong revenue and income growth were driven by the Zoetis MFA acquisition, robust vaccine and nutritional specialty performance, and positive market dynamics. Integration of the acquisition is nearly complete, with expanded geographic reach and enhanced customer offerings. Leadership transition will maintain strategic continuity.
Phibro Animal Health Corporation to Participate in Bank of America 2026 Virtual Animal Health Summit
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2026 Virtual Animal Health Summit. Chief Financial Officer, G...
Phibro Animal Health price target raised to $49 from $45 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Phibro Animal Health (PAHC) to $49 from $45 and keeps an Equal Weight rating on the shares. Phibro’s latest print reflects solid…
Phibro Animal Health Earnings Call Transcript: Q2 2026
Q2 saw 21% sales and 41% EBITDA growth, led by animal health and MFA integration. Fiscal 2026 guidance was raised for sales, EBITDA, and net income, reflecting strong demand and operational momentum. Leadership transition and new product launches support future growth.
Phibro Animal Health Earnings release: Q2 2026
Phibro Animal Health released its Q2 2026 earnings on February 5, 2026, summarizing the period's financial results.
Phibro Animal Health Quarterly report: Q2 2026
Phibro Animal Health has published its Q2 2026 quarterly earnings report on February 5, 2026.
Phibro Animal Health Slides: Q2 2026
Phibro Animal Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on February 5, 2026.